Companies Cryptocurrencies
Constellation Pharmaceuticals Inc
Constellation Pharmaceuticals Inc
Exchange: NasdaqGS
IPO Date: 19/07/2018
CEO: Mr. Jigar Raythatha
Biotechnology Healthcare 🔗
  • CNST
  • 33.99
  • 1630354176
    market cap
  • 0
If you bought

shares of Constellation Pharmaceuticals Inc (CNST) on
You would have made
Old Price $12 Current Price $12

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company is headquartered in Cambridge, Massachusetts and currently employs 82 full-time employees. The firm has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The firm is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Address: 215 1st St Ste 200 Cambridge MASSACHUSETTS 02142

Stay updated.